[Simply convincing. New fixed combination for HIV therapy].
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004338:Drug Combinations; D024882:Drug Resistance, Viral; D000068679:Emtricitabine; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D063065:Organophosphonates / Q000009:adverse effects / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010349:Patient Compliance; D017410:Practice Guidelines as Topic; D015996:Survival Rate; D000068698:Tenofovir
D019380:Anti-HIV Agents; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003841:Deoxycytidine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine